Dennis Idowu1, Katrina Merrion2, Nina Wemmer2, Janine Gessner Mash2, Barbara Pettersen2, Dusan Kijacic2, Ruth B Lathi3. 1. Department of Obstetrics and Gynecology, Kaiser Permanente Oakland Medical Center, Oakland, California. Electronic address: dennis.idowu.4@gmail.com. 2. Natera, San Carlos, California. 3. Department of Reproductive Endocrinology and Infertility, Stanford University, Palo Alto, California.
Abstract
OBJECTIVE: To report live birth rates (LBR) and total aneuploidy rates in a series of patients with balanced translocations who pursued in vitro fertilization (IVF)-preimplantation genetic diagnosis (PGD) cycles. DESIGN: Retrospective cohort analysis. SETTING: Genetic testing reference laboratory. PATIENT(S): Seventy-four couples who underwent IVF-PGD due to a parental translocation. INTERVENTION(S): IVF cycles and embryo biopsies were performed by referring clinics. Biopsy samples were sent to a single reference lab for PGD for the translocation plus 24-chromosome aneuploidy screening with the use of a single-nucleotide polymorphism (SNP) microarray. MAIN OUTCOME MEASURE(S): LBR per biopsy cycle, aneuploidy rate, embryo transfer (ET) rate, miscarriage rate. RESULT(S): The LBR per IVF biopsy cycle was 38%. LBR for patients reaching ET was 52%. Clinical miscarriage rate was 10%. Despite a mean age of 33.8 years and mean of 7 embryos biopsied, there was a 30% chance for no chromosomally normal embryos. Maternal age >35 years, day 3 biopsy, and having fewer than five embryos available for biopsy increased the risk of no ET. CONCLUSION(S): IVF-PGD for translocation and aneuploidy screening had good clinical outcomes. Patients carrying a balanced translocation who are considering IVF-PGD should be aware of the high risk of no ET, particularly in women ≥35 years old.
OBJECTIVE: To report live birth rates (LBR) and total aneuploidy rates in a series of patients with balanced translocations who pursued in vitro fertilization (IVF)-preimplantation genetic diagnosis (PGD) cycles. DESIGN: Retrospective cohort analysis. SETTING: Genetic testing reference laboratory. PATIENT(S): Seventy-four couples who underwent IVF-PGD due to a parental translocation. INTERVENTION(S): IVF cycles and embryo biopsies were performed by referring clinics. Biopsy samples were sent to a single reference lab for PGD for the translocation plus 24-chromosome aneuploidy screening with the use of a single-nucleotide polymorphism (SNP) microarray. MAIN OUTCOME MEASURE(S): LBR per biopsy cycle, aneuploidy rate, embryo transfer (ET) rate, miscarriage rate. RESULT(S): The LBR per IVF biopsy cycle was 38%. LBR for patients reaching ET was 52%. Clinical miscarriage rate was 10%. Despite a mean age of 33.8 years and mean of 7 embryos biopsied, there was a 30% chance for no chromosomally normal embryos. Maternal age >35 years, day 3 biopsy, and having fewer than five embryos available for biopsy increased the risk of no ET. CONCLUSION(S): IVF-PGD for translocation and aneuploidy screening had good clinical outcomes. Patients carrying a balanced translocation who are considering IVF-PGD should be aware of the high risk of no ET, particularly in women ≥35 years old.
Authors: Iris G Insogna; A Lanes; L Dobson; E S Ginsburg; C Racowsky; E Yanushpolsky Journal: J Assist Reprod Genet Date: 2021-03-03 Impact factor: 3.412